The preoperative lymphocyte to monocyte ratio predicts clinical outcome in patients with stage III colon cancer

British Journal of Cancer

Volumn 110, Issue 2, 2014, Pages 435-440

  Stotz, M ^a   Pichler, M ^a   Absenger, G ^a   Szkandera, J ^a   Arminger, F ^a   Schaberl Moser, R ^a   Samonigg, H ^a   Stojakovic, T ^a   Gerger, A ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

colon cancer; inflammation; lymphocytes; prognostic marker

Indexed keywords

FLUOROURACIL;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; COLON CANCER; FEMALE; HIGH RISK PATIENT; HUMAN; KAPLAN MEIER METHOD; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOCYTE; MONOCYTEL COUNT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; VERY ELDERLY; CANCER PROGNOSIS; COHORT ANALYSIS; CONFIDENCE INTERVAL; CORRELATION ANALYSIS; HAZARD RATIO; LYMPHOCYTE; LYMPHOCYTE MONOCYTE RATIO; MULTIVARIATE ANALYSIS; PREOPERATIVE PERIOD; RECEIVER OPERATING CHARACTERISTIC;

ADULT; AGED; AGED, 80 AND OVER; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOCYTES; MALE; MIDDLE AGED; MONOCYTES; NEOPLASM STAGING; PREOPERATIVE PERIOD; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES;

EID: 84892910540     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.785     Document Type: Article

References (39)

1. Absenger G, Szkandera J, Pichler M, Stotz M, Arminger F, Weissmueller M, Schaberl-Moser R, Samonigg H, Stojakovic T, Gerger A (2013) A derived neutrophil to lymphocyte ratio predicts clinical outcome in stage II and III colon cancer patients. Br J Cancer 109(2): 395-400.
2. Allavena P, Garlanda C, Borrello MG, Sica A, Mantovani A (2008) Pathways connecting inflammation and cancer. Curr Opin Genet Dev 18(1): 3-10.
3. Batty N, Ghonimi E, Feng L, Fayad L, Younes A, Rodriguez MA, Romaguera JE, McLaughlin P, Samaniego F, Kwak LW, Hagemeister Jr FB (2013) The absolute monocyte and lymphocyte prognostic index for patients with diffuse large B-cell lymphoma who receive R-CHOP. Clin Lymphoma Myeloma Leukemia 13(1): 15-18.
4. Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf AC, Angell H, Fredriksen T, Lafontaine L, Berger A, Bruneval P, Fridman WH, Becker C, Pages F, Speicher MR, Trajanoski Z, Galon J (2013) Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 39(4): 782-795.
5. Bingle L, Brown NJ, Lewis CE (2002) The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 196(3): 254-265.
6. Cho H, Hur HW, Kim SW, Kim SH, Kim JH, Kim YT, Lee K (2009) Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment. Cancer Immunol Immunother 58(1): 15-23.
7. Condeelis J, Pollard JW (2006) Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 124(2): 263-266.
8. Dunn GP, Old LJ, Schreiber RD (2004) The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21(2): 137-148.
9. Evani SJ, Prabhu RG, Gnanaruban V, Finol EA, Ramasubramanian AK (2013) Monocytes mediate metastatic breast tumor cell adhesion to endothelium under flow. FASEB J 27(8): 3017-3029.
10. Fidler IJ, Schroit AJ (1988) Recognition and destruction of neoplastic cells by activated macrophages: discrimination of altered self. Biochim Biophys Acta 948(2): 151-173.
11. Fridman WH, Pages F, Sautes-Fridman C, Galon J (2012) The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 12(4): 298-306.
12. Galon J, Mlecnik B, Bindea G, Angell HK, Berger A, Lagorce C, Lugli A, Zlobec I, Hartmann A, Bifulco C, Nagtegaal ID, Palmqvist R, Masucci GV, Botti G, Tatangelo F, Delrio P, Maio M, Laghi L, Grizzi F, Asslaber M, D'Arrigo C, Vidal-Vanaclocha F, Zavadova E, Chouchane L, Ohashi PS, Hafezi-Bakhtiari S, Wouters BG, Roehrl M, Nguyen L, Kawakami Y, Hazama S,Okuno K, Ogino S,Gibbs P,Waring P, Sato N, Torigoe T, Itoh K, Patel PS, Shukla SN, Wang Y, Kopetz S, Sinicrope FA, Scripcariu V, Ascierto PA, Marincola FM, Fox BA, Pages F (2013) Towards the introduction of the Immunoscore in the classification of malignant tumors. J Pathol; e-pub ahead of print 3 October 2013; doi:10.1002/path.4287.
13. Galon J, Pages F, Marincola FM, Angell HK, Thurin M, Lugli A, Zlobec I, Berger A, Bifulco C, Botti G, Tatangelo F, Britten CM, Kreiter S, Chouchane L, Delrio P, Arndt H, Asslaber M, Maio M, Masucci GV, Mihm M, Vidal-Vanaclocha F, Allison JP, Gnjatic S, Hakansson L, Huber C, Singh-Jasuja H, Ottensmeier C, Zwierzina H, Laghi L, Grizzi F, Ohashi PS, Shaw PA, Clarke BA, Wouters BG, Kawakami Y, Hazama S, Okuno K, Wang E, O'Donnell-Tormey J, Lagorce C, Pawelec G, Nishimura MI, Hawkins R, Lapointe R, Lundqvist A, Khleif SN, Ogino S, Gibbs P, Waring P, Sato N, Torigoe T, Itoh K, Patel PS, Shukla SN, Palmqvist R, Nagtegaal ID, Wang Y, D'Arrigo C, Kopetz S, Sinicrope FA, Trinchieri G, Gajewski TF, Ascierto PA, Fox BA (2012) Cancer classification using the Immunoscore: a worldwide task force. J Transl Med 10: 205.
14. Gomez D, Farid S, Malik HZ, Young AL, Toogood GJ, Lodge JP, Prasad KR (2008) Preoperative neutrophil-to-lymphocyte ratio as a prognostic predictor after curative resection for hepatocellular carcinoma. World J Surgery 32(8): 1757-1762.
15. Heuff G, Oldenburg HS, Boutkan H, Visser JJ, Beelen RH, Van Rooijen N, Dijkstra CD, Meyer S (1993) Enhanced tumour growth in the rat liver after selective elimination of Kupffer cells. Cancer Immunol Immunother 37(2): 125-130.
16. Hoffmann TK, Dworacki G, Tsukihiro T, Meidenbauer N, Gooding W, Johnson JT, Whiteside TL (2002) Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance. Clin Cancer Res 8(8): 2553-2562.
17. Idowu OK, Ding Q, Taktak AF, Chandrasekar CR, Yin Q (2012) Clinical implication of pretreatment neutrophil to lymphocyte ratio in soft tissue sarcoma. Biomarkers 17(6): 539-544.
18. Kaneko M, Nozawa H, Sasaki K, Hongo K, Hiyoshi M, Tada N, Murono K, Nirei T, Kawai K, Sunami E, Tsuno NH, Kitayama J (2012) Elevated neutrophil to lymphocyte ratio predicts poor prognosis in advanced colorectal cancer patients receiving oxaliplatin-based chemotherapy. Oncology 82(5): 261-268.
19. Kwon HC, Kim SH, Oh SY, Lee S, Lee JH, Choi HJ, Park KJ, Roh MS, Kim SG, Kim HJ, Lee JH (2012) Clinical significance of preoperative neutrophillymphocyte versus platelet-lymphocyte ratio in patients with operable colorectal cancer. Biomarkers 17(3): 216-222.
20. Li ZM, Huang JJ, Xia Y, Sun J, Huang Y, Wang Y, Zhu YJ, Li YJ, Zhao W, Wei WX, Lin TY, Huang HQ, Jiang WQ (2012) Blood lymphocyte-tomonocyte ratio identifies high-risk patients in diffuse large B-cell lymphoma treated with R-CHOP. PloS One 7(7): e41658.
21. Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454(7203): 436-444.
22. Mlecnik B, Tosolini M, Kirilovsky A, Berger A, Bindea G,Meatchi T, Bruneval P, Trajanoski Z, Fridman WH, Pages F, Galon J (2011) Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol 29(6): 610-618.
23. Mroczko B, Groblewska M, Wereszczynska-Siemiatkowska U, Okulczyk B, Kedra B, Laszewicz W, Dabrowski A, Szmitkowski M (2007) Serum macrophage-colony stimulating factor levels in colorectal cancer patients correlate with lymph node metastasis and poor prognosis. Clin Chim Acta 380(1-2): 208-212.
24. Mytar B, Baj-Krzyworzeka M, Majka M, Stankiewicz D, Zembala M (2008) Human monocytes both enhance and inhibit the growth of human pancreatic cancer in SCID mice. Anticancer Res 28(1A): 187-192.
25. O'Connell JB, Maggard MA, Ko CY (2004) Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 96(19): 1420-1425.
26. Pollard JW (2004) Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 4(1): 71-78.
27. Pollard JW (2009) Trophic macrophages in development and disease. Nat Rev Immunol 9(4): 259-270.
28. Porrata LF, Ristow K, Colgan JP, Habermann TM, Witzig TE, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Nowakowski GS, Thompson C, Markovic SN (2012a) Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin's lymphoma. Haematologica 97(2): 262-269.
29. Porrata LF, Ristow K, Habermann TM, Witzig TE, Colgan JP, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Nowakowski GS, Thompson C, Markovic SN (2012b) Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in nodular lymphocyte-predominant Hodgkin lymphoma. Br J Haematol 157(3): 321-330.
30. Rabinowich H, Cohen R, Bruderman I, Steiner Z, Klajman A (1987) Functional analysis of mononuclear cells infiltrating into tumors: lysis of autologous human tumor cells by cultured infiltrating lymphocytes. Cancer Res 47(1): 173-177.
31. Raungkaewmanee S, Tangjitgamol S, Manusirivithaya S, Srijaipracharoen S, Thavaramara T (2012) Platelet to lymphocyte ratio as a prognostic factor for epithelial ovarian cancer. J Gynecol Oncol 23(4): 265-273.
32. Rosenberg SA (2001) Progress in human tumour immunology and immunotherapy. Nature 411(6835): 380-384.
33. Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D, Dietrich D, Biesmans B, Bodoky G, Barone C, Aranda E, Nordlinger B, Cisar L, Labianca R, Cunningham D, Van Cutsem E, Bosman F (2010) Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 28(3): 466-474.
34. Salazar R, Roepman P, Capella G, Moreno V, Simon I, Dreezen C, Lopez-Doriga A, Santos C, Marijnen C, Westerga J, Bruin S, Kerr D, Kuppen P, van de Velde C, Morreau H, Van Velthuysen L, Glas AM, Van't Veer LJ, Tollenaar R (2011) Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J Clin Oncol 29(1): 17-24.
35. Sangaletti S, Di Carlo E, Gariboldi S, Miotti S, Cappetti B, Parenza M, Rumio C, Brekken RA, Chiodoni C, Colombo MP (2008) Macrophage-derived SPARC bridges tumor cell-extracellular matrix interactions toward metastasis. Cancer Res 68(21): 9050-9059.
36. Schmoll HJ, Van Cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K, Nordlinger B, van de Velde CJ, Balmana J, Regula J, Nagtegaal ID, Beets-Tan RG, Arnold D, Ciardiello F, Hoff P, Kerr D, Kohne CH, Labianca R, Price T, Scheithauer W, Sobrero A, Tabernero J, Aderka D, Barroso S, Bodoky G, Douillard JY, El Ghazaly H, Gallardo J, Garin A, Glynne-Jones R, Jordan K, Meshcheryakov A, Papamichail D, Pfeiffer P, Souglakos I, Turhal S, Cervantes A (2012) ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Annals Oncol 23(10): 2479-2516.
37. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63(1): 11-30.
38. Swann JB, Vesely MD, Silva A, Sharkey J, Akira S, Schreiber RD, Smyth MJ (2008) Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis. Proc Natl Acad Sci USA 105(2): 652-656.
39. Zikos TA, Donnenberg AD, Landreneau RJ, Luketich JD, Donnenberg VS (2011) Lung T-cell subset composition at the time of surgical resection is a prognostic indicator in non-small cell lung cancer. Cancer Immunol Immunother 60(6): 819-827.